E-Selectin

E-Selectin, also known as CD62E antigen, is a cell adhesion molecule expressed only on cytokine activated endothelial cells. Soluble E-Selectin arises from proteolytic cleavage of the surface-expressed molecule. It is found in serum and plasma of healthy individuals, with elevated levels seen in certain immune conditions. Its role as a pro-inflammatory molecule is unclear.

Swiss-Prot Accession Number: P16581


Publications
Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury (2018) Proudfood A, Bayliffe A, O'Kane C, Wright T, Serone A, Bareille P, Brown V, Hamid U, Chen Y, Wilson R, Cordy J, Morley P, de Wildt Ruud, Elborn S, Hind M, Chilvres E, Griffiths M, Summers C, McAuley D Thorax
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Allostatic load is associated with psychotic symptoms and decreases withantipsychotic treatment in patients with schizophrenia and ?rst-episodepsychosis (2018) Berger M, Juster RP, Westphal S, Amminger P, Bogerts B, Schiltz K, Bahn S, Steiner J, Sarnyai Z Psychoneuroendocrinology
Proteomic biomarkers of cognitive impairment in obstructive sleep apnea syndrome (2018) Lal C, Hardiman G, Kumbhare S, Strange C Sleep and Breathing
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study (2018) Charnigo RJ, Beidler D, Rybin D, Pittman DD, Tan B, Howard J, Michelson AD, Frelinger AL II, Clark N Clinical and Translational Science
Sjögren’s Syndrome Patients with Ectopic Germinal Centers Present with a Distinct Salivary Proteome (2016) Delaleu N, Mydel P, Brun JG, Jonsson MV, Alimonti A, Jonsson R Rheumatology
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. (2016) Söderlund S, Christiansson L, Persson I, Hjorth-Hansen H, Richter J, Simonsson B, Mustjoki S, Olsson-Strömberg U, Loskog A. Leuk Res
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (2015) Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H and Talpaz M Blood Cancer Journal
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics (2014) Berger T, Jacob C, Haas J, Ransmayr G, Guger M, Zettl UK, Di Pauli F, Taumberger B, Wietek S, Meuer S, Reindl M, Giese T Journal of Neuroimmunology DOI: 10.1016/j.jneuroim.2014.10.001